BioAmber Inc. today announced that Robert Frost is joining its board of directors, effective today.
Mr. Frost will fill one of the board seats vacated by the resignations of Jean-Francois Huc and George F.J. Gosbee effective May 12, 2017 and May 11, 2017, respectively. Mr. Frost is a Partner at Naxos Capital Partners, one of the Company’s largest stockholders. Mr. Frost brings extensive financial experience and deep knowledge of the Company, its business and its industry. Mr. Frost has been elected a Class II director, to hold office until the 2018 annual meeting of stockholders. Please refer to the Company’s recently filed Current Report on Form 8-K for additional information related to the changes to the Company’s board of directors.
The Company is also pleased to announce the appointment of Mario Settino as the Company’s Chief Financial Officer. Mr. Settino replaces the Company’s current Interim Chief Financial Officer, Raymond Land, who will continue to serve as Chairman of the Company’s Board of Directors. Mr. Settino is seasoned professional with over 30 years of financial and operational experience in various industries such as services, manufacturing and high-end technology. He previously served as President and Chief Financial Officer of Peds Legwear and prior to this was Chief Financial Officer of Miranda Technologies. Mr. Settino has previously held senior financial positions with Loblaws, Bombardier and LGS, (an IBM company). He is a chartered professional accountant who began his career at Deloitte.
Finally, the Company is also pleased to announce that at the Company’s Annual Meeting of Stockholders held in Montreal, Canada on May 11, 2017, the Company’s stockholders voted to re-elect Kurt Briner and Ellen B. Richstone to the Company’s board of directors and to ratify the appointment of Deloitte LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2017.
Source: Street Insider
Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.
Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.
The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world.